Hegseth Orders Annual Testosterone Tests for Every Service Member Over 30 in a 'High-T Department'

Defense Secretary Pete Hegseth has ordered the U.S. military to begin screening the hormone levels of hundreds of thousands of troops, making annual testosterone testing a mandatory part of the routine physical for every active-duty and reserve service member aged 30 and older. The policy, announced July 15 and effective immediately, folds the blood test into the Periodic Health Assessment that troops already complete each year. Service members under 30 can request the screening voluntarily.

Hegseth rolled the policy out in a social media video branded the "High-T Department," framing hormone levels as a matter of combat readiness rather than routine medicine. Keeping testosterone in range, he said, was a way to keep troops on the "leading edge of lethality." In a separate written memo, he tied the initiative to what military medicine calls Operator Syndrome — the cluster of endocrine, sleep and musculoskeletal problems documented in special operations veterans after years of high-tempo deployments. "Operator Syndrome represents a unique convergence of health challenges that require proactive clinical intervention," Hegseth wrote, arguing that "applying lessons learned from treating Operator Syndrome across the total force including targeted testosterone therapy directly optimizes warfighter readiness."

Treatment is not compulsory. If a screening comes back low and a physician recommends it, a service member may accept or decline testosterone replacement therapy. But the mandatory provision in the written memo does not distinguish between male and female troops, and the Pentagon has not said whether women will be exempted in practice. The department also has not identified the research base behind the decision, declining to answer questions about which studies underpin a total-force screening program.

The clinical picture is more complicated than a single number. The Endocrine Society puts the normal range for adult men at roughly 300 to 1,000 nanograms per deciliter; for adult women the range is a fraction of that, about 15 to 46 ng/dL by the Cleveland Clinic's measure. Levels fall naturally by 1% to 2% a year beginning somewhere between ages 30 and 40. A genuine diagnosis of low testosterone requires two separate morning blood draws below roughly 280 to 320 ng/dL, paired with actual symptoms such as fatigue, muscle loss or low libido — and about 30% of borderline first results come back normal on the repeat test.

That gap between a single low reading and a real diagnosis is where doctors see trouble. Testosterone replacement therapy can restore energy, bone density and metabolic function, but it also suppresses the body's own production. "When you take outside testosterone, your body stops making its own," said Dr. Ravi Iyengar, an endocrinologist at UC San Diego. The documented risks include infertility and testicular shrinkage, worsened sleep apnea, acne, prostate enlargement, and an elevated risk of blood clots and stroke — a meaningful list for a population whose job requires long deployments and sustained physical exertion.

There is also an irony the Pentagon has not addressed. Testosterone therapy is the same intervention that constitutes gender-affirming care for transgender service members — a category of medical treatment this administration has moved aggressively to restrict inside the armed forces. No FDA-approved testosterone product exists for women at all; any prescription written for a female service member would be off-label, typically a compounded cream at a fraction of the male dose.